Skip to main content
SpringerLink
Log in

Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Atorvastatin has been extensively studied in the primary and secondary prevention of cardiovascular events, and may have some clinical advantages over various other statins in these respects. The principal primary prevention study of atorvastatin, ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm), revealed that atorvastatin reduced the relative risk of primary coronary heart disease (CHD) events by 36% (p = 0.0005) compared with placebo in patients with hypertension. Much published data confirm the secondary preventive benefits of atorvastatin in various clinical settings. The IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) and TNT (Treating to New Targets) trials demonstrate the preventive efficacy of atorvastatin in patients with stable CHD. Relative to simvastatin (in the IDEAL trial) and low-dosage atorvastatin (in the TNT trial), intensive atorvastatin therapy (80 mg/day) reduced the risk of nonfatal myocardial infarction (MI) by 17–22% (p < 0.02). Furthermore, the ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events) and GREACE (GREek Atorvastatin and Coronary-heart-disease Evaluation) trials highlight the benefits of atorvastatin in the ‘real world’ setting in patients with stable CHD. Compared with ‘usual’ care, atorvastatin reduced the risk of nonfatal MI by 47–59% (p < 0.0002).

Moreover, the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering), PROVE-IT (PRavastatin Or atorVastatin Evaluation and Infection Therapy) and IDEAL-ACS (Acute Coronary Syndromes) studies outline the benefits of high-dosage atorvastatin therapy started within 24–96 hours, 10 days or 2 months, respectively, of an acute coronary syndrome. Relative to placebo, pravastatin and simvastatin, atorvastatin reduced the risk of death or major cardiovascular events by 16–18% (p ≤ 0.048). In patients undergoing revascularisation procedures, the AVERT (Atorvastatin VErsus Revascularisation Treatment) study revealed that 18 months’ administration of atorvastatin 80 mg/day was at least as effective as angioplasty plus usual care in reducing the risk of ischaemic events in low-risk patients with stable coronary artery disease. Furthermore, the ARMYDA (Atorvastatin for Reduction in MYocardial DAmage during angioplasty) and ARMYDA-3 trials showed that 7 days’ administration of atorvastatin 40 mg/day before coronary intervention significantly reduced the risks of periprocedural myocardial damage (ARMYDA), postprocedural MI (p = 0.025; ARMYDA) and atrial fibrillation (p = 0.003; ARMYDA-3) versus placebo. In addition, it has been reported that C-reactive protein levels and the combined incidence of cardiovascular events (death, MI and target segment revascularisation during the 6-month follow-up) were significantly higher in coronaropathic patients undergoing non-surgical revascularisation procedures (stent implantation) not receiving statin therapy compared with those treated with atorvastatin (80mg). Overall, therefore, the marked efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events underscores the pivotal place that this statin has in general cardiovascular disease management, and suggests even greater potential clinical utility for the drug in some clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial, Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58

    Article  PubMed  CAS  Google Scholar 

  2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA 1998; 279: 1615–22

    Article  PubMed  CAS  Google Scholar 

  3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholester-olemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

    CAS  Google Scholar 

  4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007

    Article  Google Scholar 

  5. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 215–9

    Article  Google Scholar 

  6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504

    Article  PubMed  CAS  Google Scholar 

  7. Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004; 44: 1772–9

    PubMed  Google Scholar 

  8. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35

    Article  PubMed  CAS  Google Scholar 

  9. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674–8

    Article  PubMed  CAS  Google Scholar 

  10. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455–61

    Article  PubMed  CAS  Google Scholar 

  11. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after MI, the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45

    Article  PubMed  CAS  Google Scholar 

  12. Pedersen TR, Olsson AG, Carter NB, et al. Comparison of the efficacy of intensive atorvastatin versus standard simvastatin therapy in patients with acute coronary syndrome: the IDEAL trial [abstract no. 5015]. 28th Annual Congress of the European Society of Cardiology; 2006 Sep 2–6; Barcelona, Spain. Eur Heart J 2006; 27 Suppl.: 856–7

    Article  Google Scholar 

  13. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6

    Article  PubMed  CAS  Google Scholar 

  14. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes, the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–8

    Article  PubMed  CAS  Google Scholar 

  15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  16. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005; 96(5A): 54–60F

    Article  Google Scholar 

  17. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405–10

    Article  PubMed  CAS  Google Scholar 

  18. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292: 1365–7

    Article  PubMed  CAS  Google Scholar 

  19. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–8

    Article  PubMed  CAS  Google Scholar 

  20. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80mg and pravastatin 40mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005; 45: 1644–8

    Article  PubMed  CAS  Google Scholar 

  21. Gaspardone A, Versaci F, Proietti I, et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and 6-month clinical events. Am J Cardiol 2002; 90(7): 786–9

    Article  PubMed  CAS  Google Scholar 

  22. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906

    Article  PubMed  Google Scholar 

  23. Sever PS, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8

    Article  PubMed  CAS  Google Scholar 

  24. Sever PS, Dahlof B, Poulter N, et al. Lipid Lowering Arm (ASCOT LLA) revisited: interaction of antihypertensive and lipid lowering therapy [abstract]. Circulation 2005; 112 Suppl. II: A730

    Google Scholar 

  25. Pasternak RC. The ALLHAT lipid lowering trial: less is less. JAMA 2002, 4

  26. Ray KK, Cannon CP. Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother 2005; 6: 915–27

    Article  PubMed  CAS  Google Scholar 

  27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  28. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9

    Article  PubMed  CAS  Google Scholar 

  29. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

    Article  Google Scholar 

  30. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78

    Article  PubMed  CAS  Google Scholar 

  31. Grundy SM. The changing face of cardiovascular risk. J Am Coll Cardiol 2005; 46: 173–5

    Article  PubMed  Google Scholar 

  32. Schwartz GG, Olsson AG. The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol 2005; 96(5A): 45–53F

    Article  Google Scholar 

  33. Thompson PL, Meredith I, Amerena J, et al. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute MI or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial [abstract]. Am Heart J 2004; 148: e2

    Article  PubMed  Google Scholar 

  34. Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infraction: a randomized trial. Eur Heart J 2002; 23: 1931–7

    Article  PubMed  CAS  Google Scholar 

  35. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16

    Article  PubMed  Google Scholar 

  36. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006; 113: 1406–14

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The preparation of this manuscript has been sponsored by Pfizer Italia, who proposed the initial idea of the review. Prof. Marcello Arca and Dr Achille Gaspardone have the responsibility of reported data as well as of their interpretation. The sponsor had no role in the approval of the manuscript. Dr Achille Gaspardone has served as consultant and received speaker honoraria from Pfizer Italia. Prof. Marcello Arca served as consultant and/or received speaker honoraria from Merck Sharp & Dhome, AstraZeneca, Simesa, Sanofi Aventis, Pfizer, Guidotti and Neopharmed. The authors wish to thank Dr Michelangelo Barone from the Medical Department of Pfizer Italia for his technical support in collecting part of the material used in this paper. Editorial support for the preparation of the manuscript was provided by Wolters Kluwer Health Medical Communications.

Author information

Authors and Affiliations

  1. Department of Clinical and Therapeutic Medicine, La Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161, Rome, Italy

    Marcello Arca

  2. Cardiology Department, Ospedale S. Eugenio, Rome, Italy

    Achille Gaspardone

Authors
  1. Marcello Arca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Achille Gaspardone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Arca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arca, M., Gaspardone, A. Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs 67 (Suppl 1), 29–42 (2007). https://doi.org/10.2165/00003495-200767001-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767001-00004

Keywords

Search

Navigation